ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

Value outperformed in 2022, with the Russell 1000 Value index falling about 7.5 percent compared to a more than 29 percent decline for the Russell 1000 Growth index. But that tren ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,137 calls trading, 1.3x expected, and implied vol increasing almost 2 points ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $40.02 which represents a decrease of $-1.05 or -2.56% from the prior close of $41.07. The stock opened at $40.76 and touched a low ...

I maintain a buy rating on VB due to its reasonable valuation, solid earnings growth, and bullish chart, despite a recent 10% ...

Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications ...